Abstract
Aims: Nanobodies, characterized by their small size, accessibility, and high yield, are emerging as advantageous tools in various applications. Despite these benefits, their integration into the formulation of immunoturbidimetric reagents has remained limited since their discovery.
 Methodology: This study utilized nanobodies specific to cystatin C to formulate immunoturbidimetric reagents and compared them with traditional rabbit polyclonal antibody reagents. 
 Results: The findings revealed that the multiantibody affinity of Cys-rPAB surpasses that of Cys-VHH-104 and Cys-VHH-704 nanobodies, although the difference is not statistically significant. Upon evaluating the reagent formulation performance, both types of antibodies were found to satisfy the prerequisites of conventional immunoturbidimetric assay reagents. The correlation coefficient R2 in the statistical analysis of the clinical results was 0.9986, signifying a high degree of consistency.
 Conclusion: These findings underscore the feasibility and considerable economic potential of employing nanobodies in immunoturbidimetric reagents.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Advances in Biology & Biotechnology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
